Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials
Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.
You may also be interested in...
Consumer health companies are starting to step into the lucrative but fast-changing and complex EU cannabidiol market. But what are the key considerations for firms before making such a move, or if they have already? HBW Insight speaks to CBD regulatory expert Greer Deal.
Vitamin Shoppe rolls out CBD HQ sections in 572 stores in 39 states, citing strong word-of-mouth demand for products. The national retailer’s move could reflect growing bullishness by industry after FDA sent unpublished draft guidance on CBD enforcement for White House clearance.
A diclofenac topical analgesic is first, likely followed by a line extension for its Prevacid 24HR PPI brand. Perrigo also plans to introduce natural-based products that “leverage our expertise in Europe."